Patent ID: 8735380

Claim:
A pharmaceutical tablet for oral administration comprising from 3 to 18 wt % ulipristal acetate, wherein ulipristal acetate is present in an amount ranging from 1 mg to 50 mg, from 60 to 95 wt % of a diluent selected from the group consisting of lactose monohydrate, microcrystalline cellulose, mannitol and combinations thereof, from 0 to 10 wt % of a binding agent, from 1 to 10 wt % of croscarmellose sodium, and from 0.5 to 5 wt % of magnesium stearate, wherein the tablet is an oral tablet, and wherein at least 80% (w/w) of ulipristal acetate present in the tablet is dissolved within about 20 minutes when the tablet is subjected to an in vitro dissolution assay in a paddle apparatus at 37° C.±0.5° C., and pH=1.